Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
PCRX Stock Chart & Stats
$23.26
-$0.08(-0.43%)
At close: 4:00 PM EST
$23.26
-$0.08(-0.43%)
Day’s Range― - ―
52-Week Range$18.80 - $27.64
Previous CloseN/A
Volume54.84K
Average Volume (3M)813.26K
Market Cap
$941.79M
Enterprise Value$1.30B
Total Cash (Recent Filing)$238.42M
Total Debt (Recent Filing)$454.38M
Price to Earnings (P/E)164.0
Beta0.86
Next Earnings
May 06, 2026EPS Estimate
0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.57
Shares Outstanding40,489,895
10 Day Avg. Volume850,074
30 Day Avg. Volume813,264
Financial Highlights & Ratios
PEG Ratio-1.53
Price to Book (P/B)1.66
Price to Sales (P/S)1.59
P/FCF Ratio8.44
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit2.31
Enterprise Value/Ebitda10.65
Forecast
1Y Price Target
$30.60Price Target Upside31.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)2.82
Revenue Forecast (FY)$760.88M
Bulls Say, Bears Say
Bulls Say
Capital AllocationShare repurchases and remaining buyback authorization support shareholder value by reducing outstanding shares and signaling a shareholder-friendly capital allocation approach.
Commercial ExecutionA new partnership that boosted promotional capacity and a fully active sales force helped lift shipment volumes, offsetting discounting and indicating renewed commercial momentum.
Reimbursement And Commercial AccessExpanded commercial payer coverage and regulatory moves enabling separate reimbursement for non-opioid pain treatments broaden Exparel's addressable market and support wider adoption.
Bears Say
Competition And Reimbursement RiskPotential generic challengers and uncertainty around reimbursement policy pose significant downside risk to Exparel revenue if market share or coverage deteriorates.
Guidance Versus ExpectationsConservative company guidance relative to Street expectations could undermine investor confidence in projected growth and weigh on the stock.
Pricing Pressure From Purchasing AgreementsPrice discounting tied to a group purchasing agreement suppressed net pricing and tempered revenue gains, creating pressure on margins.
Pacira Pharmaceuticals News
PCRX FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $18.80 and its highest was $27.64 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Pacira Pharmaceuticals’s market cap is $941.79M.
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is May 06, 2026 which is in 50 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Feb 26, 2026. The company reported $0.57 earnings per share for the quarter, missing the consensus estimate of $0.905 by -$0.335.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is 0.61.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 40,489,895 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of $0.57 in its last earnings report, missing expectations of $0.905. Following the earnings report the stock price went down -3.01%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Currently, no hedge funds are holding shares in PCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.60 (31.56% Upside)
$30.60 (31.56% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 47.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.51%
12-Months-Change
Fundamentals
Return on Equity
0.95%
Trailing 12-Months
Asset Growth
-18.58%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
PCRX Company Deck
PCRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a broadly positive outlook: Pacira reported record gross margins, reinvigorated EXPAREL volume growth (~7% in Q4), expanded payer coverage (102M lives outside the bundle), strengthened IP (21 patents) and secured strategic partnerships (LG Chem, J&J). The company is investing in a promising pipeline (PCRX-201, PCRX-2002) and returned capital via buybacks while maintaining a healthy cash position ($238M). Offsetting items include rising R&D and SG&A (notably +56% R&D and +30% SG&A in Q4), revenue headwinds from buy-mix/discounting tied to a GPO, flat ZILRETTA sales, and near-term margin/inventory pressures. Overall, the positives (top-line momentum, margin expansion, IP runway, partnerships, and pipeline progress) outweigh the near-term cost and execution risks.View all PCRX earnings summariesPCRX Stock 12 Month Forecast
Average Price Target
$30.60
▲(31.56% Upside)
Technical Analysis
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
3.47% Insiders
24.38% Mutual Funds
12.35% Other Institutional Investors
28.39% Public Companies and
Individual Investors